The hidden epidemic: Uncovering incidental fatty liver disease and its metabolic comorbidities by datamining in a hospital data lake - A real-world cohort study

被引:1
作者
Karhiaho, Iiro P. [1 ]
Kurki, Samu H. [1 ,2 ]
Parviainen, Helka I. [3 ,4 ,5 ]
Kullamaa, Liisa [1 ]
Farkkila, Martti A. [6 ]
Matikainen, Niina [1 ,7 ]
Tuomi, Tiinamaija [1 ,2 ,7 ,8 ,9 ]
机构
[1] Helsinki Univ Hosp, Abdominal Ctr, Endocrinol, PB 340, Helsinki 00029, Finland
[2] Univ Helsinki, Inst Mol Med Finland, Helsinki, Finland
[3] Helsinki Univ Hosp, Med Imaging Ctr, Dept Radiol, Helsinki, Finland
[4] Univ Helsinki, Helsinki, Finland
[5] Vaasa Cent Hosp, Dept Radiol, Wellbeing Serv Cty Ostrobothn, Vaasa, Finland
[6] Helsinki Univ Hosp, Abdominal Ctr, Gastroenterol, Helsinki, Finland
[7] Univ Helsinki, Res Program Clin & Mol Metab, Helsinki, Finland
[8] Folkhalsan Res Ctr, Helsinki, Finland
[9] Lund Univ, Diabet Ctr, Malmo, Sweden
基金
芬兰科学院;
关键词
Fatty liver disease; Diabetes; Dyslipidemia; Screening; HEPATIC STEATOSIS; HIGH PREVALENCE; POPULATION; FIBROSIS; ASSOCIATION; ULTRASOUND; DIAGNOSIS; INSIGHTS; ADULTS; NAFLD;
D O I
10.1016/j.diabres.2024.111609
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aims: To identify individuals with incidental fatty liver disease (FLD), and to evaluate its prevalence, metabolic co -morbidities and impact on follow-up. Methods: We leveraged the data -lake of Helsinki Uusimaa Hospital district (Finland) with a population of 1.7 million (specialist and primary care). A phrase recognition script on abdominal imaging reports (2008-2020) identified/excluded FLD or cirrhosis; we extracted ICD-codes, laboratory and BMI data. Results: Excluding those with other liver diseases, the prevalence of FLD was 29% (steatosis yes/no, N=61,271/ 155,521; cirrhosis, N=3502). The false positive and negative rates were 5-6%. Only 1.6% of the FLD cases had the ICD code recorded and 32% had undergone full clinical evaluation for associated co -morbidities. Of the 35-65 -year -old individuals with FLD, 20% had diabetes, 42% prediabetes and 28% a high liver fibrosis index. FLD was independently predicted by diabetes (OR 1.56, CI 1.46-1.66, p = 2.3 * 10"-41), BMI (1.46, 1.42-1.50, p = 1.7 * 10"-154) and plasma triglyceride level (1.5, 1.43-1.57, p = 3.5 * 10"-68). Alanine aminotransferase level mildly increased (1.12, 1.08-1.16, p = 2.2 * 10"-9) and high age decreased the risk (0.92, 0.89-0.94, p = 4.65*10"-09). Half of the cases had normal ALT. Conclusions: The incidental radiological finding of FLD is reliable and associated with metabolic risks but largely ignored, although it should lead to metabolic and hepatic follow-up.
引用
收藏
页数:9
相关论文
共 46 条
[1]   Development and validation of a model to predict incident chronic liver disease in the general population: The CLivD score [J].
aberg, Fredrik ;
Luukkonen, Panu K. ;
But, Anna ;
Salomaa, Veikko ;
Britton, Annie ;
Petersen, Kasper Meidahl ;
Bojesen, Stig Egil ;
Balling, Mie ;
Nordestgaard, Borge G. ;
Puukka, Pauli ;
Mannisto, Satu ;
Lundqvist, Annamari ;
Perola, Markus ;
Jula, Antti ;
Farkkila, Martti .
JOURNAL OF HEPATOLOGY, 2022, 77 (02) :302-311
[2]   Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables [J].
Ahlqvist, Emma ;
Storm, Petter ;
Karajamaki, Annemari ;
Martinell, Mats ;
Dorkhan, Mozhgan ;
Carlsson, Annelie ;
Vikman, Petter ;
Prasad, Rashmi B. ;
Aly, Dina Mansour ;
Almgren, Peter ;
Wessman, Ylva ;
Shaat, Nael ;
Spegel, Peter ;
Mulder, Hindrik ;
Lindholm, Eero ;
Melander, Olle ;
Hansson, Ola ;
Malmqvist, Ulf ;
Lernmark, Ake ;
Lahti, Kaj ;
Forsen, Tom ;
Tuomi, Tiinamaija ;
Rosengren, Anders H. ;
Groop, Leif .
LANCET DIABETES & ENDOCRINOLOGY, 2018, 6 (05) :361-369
[3]   Real-world data reveal a diagnostic gap in non-alcoholic fatty liver disease [J].
Alexander, Myriam ;
Loomis, A. Katrina ;
Fairburn-Beech, Jolyon ;
van der Lei, Johan ;
Duarte-Salles, Talita ;
Prieto-Alhambra, Daniel ;
Ansell, David ;
Pasqua, Alessandro ;
Lapi, Francesco ;
Rijnbeek, Peter ;
Mosseveld, Mees ;
Avillach, Paul ;
Egger, Peter ;
Kendrick, Stuart ;
Waterworth, Dawn M. ;
Sattar, Naveed ;
Alazawi, William .
BMC MEDICINE, 2018, 16
[4]  
Alves-Bezerra M, 2018, COMPR PHYSIOL, V8, P1, DOI [10.1002/j.2040-4603.2018.tb00008.x, 10.1002/cphy.c170012]
[5]  
Amer Diabet Assoc, 2010, DIABETES CARE, V33, pS11, DOI [10.2337/dc11-S011, 10.2337/dc10-S062, 10.2337/dc10-S011, 10.2337/dc14-S081, 10.2337/dc12-s064, 10.2337/dc13-S067, 10.2337/dc12-s011, 10.2337/dc13-S011, 10.2337/dc11-S062]
[6]  
[Anonymous], 2016, Diabetologia, V64, P1388, DOI [DOI 10.1016/J.JHEP.2015.11.004, 10.1016/j.jhep.2015.11.004]
[7]   Prevalence of hepatic steatosis in an urban population in the United States: Impact of ethnicity [J].
Browning, JD ;
Szczepaniak, LS ;
Dobbins, R ;
Nuremberg, P ;
Horton, JD ;
Cohen, JC ;
Grundy, SM ;
Hobbs, HH .
HEPATOLOGY, 2004, 40 (06) :1387-1395
[8]   Noninvasive Assessment of Liver Disease in Patients With Nonalcoholic Fatty Liver Disease [J].
Castera, Laurent ;
Friedrich-Rust, Mireen ;
Loomba, Rohit .
GASTROENTEROLOGY, 2019, 156 (05) :1264-+
[9]   Prevalence of NAFLD, MAFLD and associated advanced fibrosis in the contemporary United States population [J].
Ciardullo, Stefano ;
Perseghin, Gianluca .
LIVER INTERNATIONAL, 2021, 41 (06) :1290-1293
[10]   High Prevalence of Advanced Liver Fibrosis Assessed by Transient Elastography Among US Adults With Type 2 Diabetes [J].
Ciardullo, Stefano ;
Monti, Tommaso ;
Perseghin, Gianluca .
DIABETES CARE, 2021, 44 (02) :519-525